Currently, semaglutide is only FDA-approved for: Type 2 diabetes (as Ozempic or Rybelsus) Weight management in those who are considered obese, or overweight with certain health risk factors (as Wegovy) Why pelvic health PT still matters
Use within 28 days for maximum potency and safety
Rechargeable options available for continuous temperature control
June 8, 2024: Only 12 new lawsuits were filed into the Ozempic class action MDL during May of 2024
The SUSTAIN trial program, which evaluated semaglutide for type 2 diabetes across multiple Phase 3 studies enrolling thousands of participants, did not identify urinary tract infections as a statistically significant adverse event compared to placebo
According to the Summary of Product Characteristics (SmPC), serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with semaglutide in post-marketing surveillance